Why doing nothing is the fastest way to lose everything

One of the greatest advantages I have in my role – across executive search, advisory work and leadership networks – is access. Not just to leaders themselves, but to the conversations that happen before decisions are announced and before results are visible. And after years of speaking with healthcare and life sciences leaders around the world, one pattern has become impossible to ignore: the organisations that make the greatest progress are rarely those with the most resources or the most advanced technology. They are the ones led by people willing to make decisions earlier and act with confidence, even when the path forward is not fully defined.

That is increasingly creating a clear divide. The leadership teams pulling ahead are the ones who move with purpose, align quickly around priorities and take action before certainty arrives. The others spend longer debating risk, waiting for alignment or delaying decisions until more information is available, putting them at risk of falling behind. 

What many underestimate is how far-reaching those decisions are. Leadership behaviour does not stay internal. It shapes how the organisation is perceived long before any formal interaction takes place. Talent forms a view before they engage. Customers assess credibility before you pitch. Investors build confidence before the first meeting. In a competitive market, those signals accumulate quickly, and once confidence begins to erode, it is difficult to rebuild.

This becomes particularly clear at the point where leadership decisions need to translate innovation into commercial outcomes.

It came up recently in a conversation with a contact in Canada.

“Surely, if the research is good enough, you should be able to commercialise it,” I said.

“No,” my contact replied. “Sometimes you have a product that’s not very good but is very cleverly marketed and successfully commercialised. And sometimes you get an amazing product, but they don’t commercialise it well.”

For leaders, that distinction is critical. Commercialisation is not simply a technical or scientific challenge, but is a leadership one. It requires clear direction, timely decision-making and the ability to align teams around a pathway to market.

This is where the gap is becoming more visible. In markets like Australia, the capability is not the constraint. The country has the innovation, expertise and infrastructure to compete globally. What is often missing is speed — specifically, the speed at which leadership decisions translate innovation into outcomes. The recent Ambitious Australia Strategic Examination of R&D report makes this explicit, calling for stronger pathways from research to commercialisation and greater private sector investment to support that transition.

By contrast, other markets have been more deliberate about closing that gap. In markets like China, for example, government strategy has focused on accelerating the movement of research into market use through incubators, public–private partnerships and faster regulatory pathways. The difference is not just structural. It reflects a more decisive approach to turning capability into outcomes, one that reduces the lag between discovery and execution.

The implication for leaders is clear. Waiting for complete certainty may feel prudent, particularly in an environment of financial pressure and heightened scrutiny. But in a market where capital, talent and partnerships move quickly, hesitation carries its own cost. It slows momentum, weakens confidence and reduces the likelihood of capturing opportunities at the right time.